Monitor for legal action or settlement between Xencor and Alexion regarding the royalty dispute, which could impact Xencor's future revenue and valuation. The outcome will be critical for assessing Xencor's financial trajectory despite maintained cash runway.
Price Chart
Executive Summary
Xencor Inc. announced that Alexion Pharmaceuticals disputes its obligation to pay U.S. royalties on Ultomiris sales, potentially forfeiting $100-120 million in expected revenue through 2028. Xencor disagrees with Alexion's position and is evaluating its options, while maintaining its cash guidance of $380-400 million by end-2026 and sufficient runway into mid-2028.
Key Facts
- Alexion Pharmaceuticals disputes obligation to pay U.S. royalties on Ultomiris sales and will not make future U.S. payments
- Xencor expected $100-120 million in additional U.S. royalties through 2028 based on patent issuance
- Xencor disagrees with Alexion's position and is evaluating its options
- Xencor maintains cash guidance of $380-400 million at end-2026 and sufficient runway into mid-2028
- Alexion will continue making royalty payments for Ultomiris sales outside the United States
Financial Impact
Loss of $100-120 million in expected royalty revenue through 2028
Risk Factors
- Potential loss of $100-120 million in expected royalty revenue
- Legal costs and uncertainty from potential litigation with Alexion
- Impact on future partnerships if intellectual property rights enforcement is perceived as weak
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000021 |
| Document: xncr-20260304xexx991.htm | 0001326732-26-000021 |
| Document: 0001326732-26-000021-index-headers.html | 0001326732-26-000021 |
| Document: 0001326732-26-000021-index.html | 0001326732-26-000021 |
| Document: 0001326732-26-000021.txt | 0001326732-26-000021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $20.00 $26.62 | ▲ +33.10% | ▲ +32.50% | $24.71 (+23.55%) |
Jun 17, 2026 15w ago | Insider Cluster | $12.64 $14.95 | ▲ +18.28% | ▲ +17.74% | $24.71 (+95.49%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $24.71 (+102.38%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $24.71 (+102.38%) |
May 6, 2026 21w ago | 8-K | $12.31 $11.42 | ▲ +7.23% | ▲ +10.37% | $24.71 (−100.73%) |
May 5, 2026 21w ago | 8-K | $12.85 $11.21 | ▼ −12.76% | ▼ −17.72% | $24.71 (+92.30%) |
Apr 27, 2026 22w ago | 8-K | $12.15 $11.63 | ▼ −4.28% | ▼ −9.75% | $24.71 (+103.37%) |
Mar 5, 2026 30w ago | Insider Cluster | $11.16 $12.81 | ▲ +14.78% | ▲ +18.57% | $24.71 (+121.42%) |
Mar 4, 2026 30w ago | 8-K | $11.16 $12.81 | ▼ −14.78% | ▼ −18.57% | $24.71 (−121.42%) |
Feb 25, 2026 31w ago | 8-K | $11.98 $12.40 | ▲ +3.51% | ▲ +8.74% | $24.71 (+106.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access